Trial Profile

A double-blind, prospective, randomized phase II/III trial of VYD-2311 for prevention of COVID-2019 infections

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Oct 2025 New trial record
04 Sep 2025 According to an Invivyd media release, this study has a randomized, placebo-controlled design with more than 100 patients per arm, powered to generate definitive, reliable evidence.
04 Sep 2025 According to an Invivyd media release, Drs. Amy Proal and David Putrino will present, on behalf of SPEAR study group, the proposed clinical study design for funding consideration by RECOVER-TLC- an NIH initiative devoted to testing potential treatments for Long COVID, on September 10, 2025 at 9:25 a.m. ET. at the Second Annual RECOVER-TLC Workshop being held September 9-10, 2025 in Bethesda, Maryland.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com